Treatment of recurrent intracranial hemangiopericytoma with SRC-related tyrosine kinase targeted therapy: A case report

Case Reports in Oncology

Volumn 3, Issue 1, 2010, Pages 93-97

  Peters, Katherine B ^a   McLendon, Roger ^a   Morse, Michael A ^a   Vredenburgh, James J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dasatinib; Hemangiopericytoma; SRC related tyrosine kinase

Indexed keywords

DASATINIB; DIHYDROTACHYSTEROL; FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SODIUM DIHYDROGEN PHOSPHATE;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; BONE PAIN; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; CHRONIC OTITIS MEDIA; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; GAMMA KNIFE RADIOSURGERY; GENE OVEREXPRESSION; HEMANGIOPERICYTOMA; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; PARANEOPLASTIC SYNDROME; PARATHYROIDECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR RECURRENCE; TYMPANOSTOMY TUBE; VASCULAR TUMOR;

EID: 77958549767     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000307468     Document Type: Article

References (15)

1. Koch M, Nielsen GP, Yoon SS: Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol 2008;97:321-329.
2. Bergers G, Song S: The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005;7:452-464.
3. Espat NJ, Lewis JJ, Leung D, Woodruff JM, Antonescu CR, Shia J, Brennan MF: Conventional hemangiopericytoma: modern analysis of outcome. Cancer 2002;95:1746-1751.
4. Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG: Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 1989;25:514-522.
5. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, et al: Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28:1-30.
6. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG: Management of recurrent meningeal hemangiopericytoma. Cancer 1998;82:1915-1920.
7. Jaaskelainen J, Louis DN, Paulus W: World Health Organization classification of tumours: pathology and genetics of tumours of the nervous system; in Kleihues P, Cavenee WK (eds): Haemangiopericytoma. Lyon, 2000, pp 190-192.
8. Mena H, Ribas JL, Pezeshkpour GH, Cowan DN, Parisi JE: Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 1991;22:84-91.
9. Fountas KN, Kapsalaki E, Kassam M, et al: Management of intracranial meningeal hemangiopericytomas: outcome and experience. Neurosurg Rev 2006;29:145-153.
10. Dufour H, Mellus P, Fuentes S, et al: Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery 2001;48:756-762; discussion 762-763.
11. Dietzmann K, von Bossanyi P, Warich-Kirches M, et al: Immunohistochemical detection of vascular growth factors in angiomatous and atypical meningiomas, as well as hemangiopericytomas. Pathol Res Pract 1997;193:503-510.
12. Lombardo LJ, Lee FY, Chen P, et al: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661.
13. Steinberg M: Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007;29:2289-2308.
14. Giles FJ, O'Dwyer M, Swords R: Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009;23:1698-1707.
15. Kantarjian H, O'Brien S, Talpaz M, et al: Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109:1556-1560.